<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DA82066A-2B1B-412F-8D72-43273A319CA6"><gtr:id>DA82066A-2B1B-412F-8D72-43273A319CA6</gtr:id><gtr:name>Roche</gtr:name><gtr:address><gtr:line1>PRG Building 93 room 6 10</gtr:line1><gtr:line2>F Hoffman La Roche</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DA82066A-2B1B-412F-8D72-43273A319CA6"><gtr:id>DA82066A-2B1B-412F-8D72-43273A319CA6</gtr:id><gtr:name>Roche</gtr:name><gtr:address><gtr:line1>PRG Building 93 room 6 10</gtr:line1><gtr:line2>F Hoffman La Roche</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F53C31AE-2246-4E36-81FD-5920FC878740"><gtr:id>F53C31AE-2246-4E36-81FD-5920FC878740</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Shima</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4E5537BD-29F6-4477-96A8-8C511FCB3CD5"><gtr:id>4E5537BD-29F6-4477-96A8-8C511FCB3CD5</gtr:id><gtr:firstName>Imre</gtr:firstName><gtr:surname>Lengyel</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3C82884D-3FB9-407F-943D-6355EBA28BA7"><gtr:id>3C82884D-3FB9-407F-943D-6355EBA28BA7</gtr:id><gtr:firstName>Valerie</gtr:firstName><gtr:surname>Lund</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800946"><gtr:id>917FED2B-1323-4EC0-BD4B-370899D7C07C</gtr:id><gtr:title>Qualifying mouse models of spontaneous, progressive age-related macular degeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800946</gtr:grantReference><gtr:abstractText>Age-related macular degeneration (AMD) is a chronic disease of the retina, which results in the loss of central vision and is the main cause of blindness in the Western World in people over 55 years age. More than 30 million people in the developed world suffer from AMD and with increasing life expectancy and changing environmental factors the incidence of AMD continues to increase. Though several treatments for AMD exist, they target ~ 20% of patients with the disease and are effective at restoring vision to a minority of those treated. Those with visual impairment or blindness have a significant impairment in quality of life and functional independence and are a considerable burden on healthcare resources. Recent scientific studies have led to the discovery of several genes linked to inflammation and the immune system, termed the complement pathway, that appear to play a major role in the onset and progression of AMD. However, there are many different abnormalities associated with AMD, including alterations to the neurons and support tissues of the retina, improper removal of waste products and in the most severe stage, growth of chaotic and sight-threatening blood vessels and oedema. Researchers are now focused on determining which of these abnormalities are caused by the complement pathway, and therefore could be targeted by new medicines that are now being developed by pharmaceutical companies. Animal models that mimic human AMD are urgently needed to begin testing these new potential medicines. By identifying animal models that accurately reflect the abnormalities observed in AMD, we hope to test the new therapies and identify at which stage of the disease, and for which abnormalities we should focus on in human clinical trials. We propose to work in partnership with a pharmaceutical company named Jerini Ophthalmic to evaluate two mouse models of AMD, compare them to the human condition, and use the models to test an inhibitor of the complement pathway that Jerini Ophthalmic hopes to test in human clinical trials within the next 1-2 years.</gtr:abstractText><gtr:technicalSummary>Age-Related Macular Degeneration (AMD) is a chronic, progressive disease of the central retina, called the macula, which results in the loss of central vision. It is the leading cause of severe vision loss and blindness in patients over the age of fifty in the developed world. A major breakthrough in AMD research occurred following recent publication of several human genetic studies linking 3 different gene loci encoding components of the complement pathway to AMD. These data implicate the complement cascade as the first molecular pathway to target in therapeutic strategies aimed at the prevention of advanced AMD. This new therapeutic approach will hopefully improve the outcomes for the large majority of AMD patients who have no treatment options (i.e. geographic atrophy) or who do not respond to current ?wet? AMD treatments targeting Vascular Endothelial Growth Factor (VEGF). Remarkably, several complement cascade antagonists are already in early clinical testing or late-stage pre-clinical development. Yet, despite having a highly validated biological pathway to target, and several potential antagonists in drug development, the pathogenic mechanisms by which the complement cascade triggers progression from early stages of AMD to either of the sight-threatening forms, geographic atrophy or choroidal neovascularisation, are ill-understood. Clarity around at which stage of AMD progression complement-induced dysfunctions play a role will be critical for designing effective clinical trials to test this promising area of disease prevention. Progress in meeting the challenges outlined above is hampered by the lack of qualified, validated animal models that enable credible comparative studies to pinpoint a therapeutic window for the application of complement antagonists in clinical trials. In collaboration with Jerini Ophthalmic, a small ophthalmic biotech, we propose to evaluate and qualify the suitability of two mouse genetic models which together appear to recapitulate most of the pathologies associated with the progression of AMD, and to determine the comparative efficacy of VEGF and complement antagonism on disease progression.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>348025</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GSK-IoO collaboration</gtr:description><gtr:id>066816E4-0F63-451E-9725-CA9BB4D708AD</gtr:id><gtr:impact>Our POC efforts have led to the movement of compounds into clinical candidate status and have led to design and execution of one clinical trial</gtr:impact><gtr:partnerContribution>Provision of compounds for lab studies; involvement in POC and transitioning of new compounds into clinic for ophthalmic use</gtr:partnerContribution><gtr:piContribution>The lab and many other researchers at the Institute have performed POC studies on new compound candidates using our animal models and biology expertise</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Ophthalmology</gtr:department><gtr:description>New GSK collaboration</gtr:description><gtr:id>6FB34ABC-79A8-4FC6-A98B-70C4575BC4E7</gtr:id><gtr:impact>Using the novel animal model, we have validated 2 new targets and cognate compounds, which are currently being scheduled for entry to the clinic in 2011-2012</gtr:impact><gtr:partnerContribution>Through research in the animal model, we have jointly moved 2 novel compounds/formulations to clinical trials</gtr:partnerContribution><gtr:piContribution>Using the novel animal model, we have validated 2 new targets and cognate compounds, which are currently being scheduled for entry to the clinic in 2011-2012</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roche</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Hoffmann-La Roche</gtr:department><gtr:description>Roche</gtr:description><gtr:id>5987D9A9-0075-45FA-AF8C-6439E861180E</gtr:id><gtr:impact>Novel target validated using a drug currently in human clinical trials</gtr:impact><gtr:partnerContribution>Opened new lines of investigation by introducing novel targets</gtr:partnerContribution><gtr:piContribution>Using the novel model, we have validated novel therapeutic strategies for treating AMD</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roche</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Hoffmann-La Roche</gtr:department><gtr:description>New Roche collaboration</gtr:description><gtr:id>87722ACB-033F-4281-938B-8F6F1F7B5414</gtr:id><gtr:impact>Multi-disciplinary
Led to initiation of a clinical trial for a new therapeutic antibody to treat neovascular AMD</gtr:impact><gtr:partnerContribution>Provided compounds for testing</gtr:partnerContribution><gtr:piContribution>Using the model, we have achieved POC studies in preclinical assessments that have led to Clinical trial initiation in Nov 2013</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Lecture to primary student at Lochinver School</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>285ABA4C-75C9-41BB-8B84-4F978B6984E8</gtr:id><gtr:impact>75 Pupils attended a lecture on &amp;quot;Careers in Drug Development Research&amp;quot;

Follow up contact from student directly to guide</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to medical doctors and pharmaceutical company employees</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>280A2A16-51AB-4420-B708-A11308F62733</gtr:id><gtr:impact>100s of medical doctors and pharma employees were informed about the complications of anti-VEGF therapy for neuron survival

Entire filed shifting away from VEGF conept to look for new approaches</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Harvard Translational Medicine Steering group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BBD5E229-FEC5-469C-9A99-F342E3FFBDEA</gtr:id><gtr:impact>Provided advisory assistance to increase interaction with Pharma, and described the novel model and its utilities for accelerating drug development and pharma interaction

Recommendation to hire an INdustry alliance liason</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to public audiences as part of an RNIB, and RNID event, and as part of NHS events</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8AA92841-57C4-4332-948D-6536C0A9D5F7</gtr:id><gtr:impact>Numerous attendees (100's) to educational events talking about advances in healthcare and research

Increased helathcare provider and patient awareness</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lasker IDDF meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FE34A0FF-CB63-4694-838C-E466A139F651</gtr:id><gtr:impact>50 experts in diabetic retinpathy drafted new guidance on areas of focus for future research

We included srong statements on neuroprotection</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>260000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>NIHR BRC</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>D29FD7E5-E9D2-4A05-AEA2-475C26016B9E</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Use of the mouse model of AMD to determine the mechanism of action and efficacy of an NCE that entered clinical trials</gtr:description><gtr:id>976FAE91-9BEB-4EBB-801F-66B41F0C69DF</gtr:id><gtr:impact>Clinical trial</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2013079696</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>CCR3 antagonists for AMD</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>A new antagonist for AMD, starting clinical trials end of 2011</gtr:description><gtr:id>57FA1476-20DF-40ED-A685-83B406430F9E</gtr:id><gtr:impact>Oral treatment could transform AMD therapy</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>GSK</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>New Ab for AMD</gtr:description><gtr:id>F6155CC6-77A7-4CD1-B881-F52CEC3AF4D9</gtr:id><gtr:impact>ONgoing</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Roche clinical trial for AMD</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>NCT01941082</gtr:ukcrnIsctnId><gtr:url>http://clinicaltrials.gov/show/NCT01941082</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Initiated new drug development programs with GSK and Roche to find neuroprotectants for AMD/DR</gtr:description><gtr:id>39E7906A-6D47-4AE1-B587-8E69FAC21E05</gtr:id><gtr:impact>in development</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Neuroprotecctants for AMD/DR</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A new, quantitative model of spontaneous choroidal neovascularization for assessment of drug candidates for AMD without the need for laser</gtr:description><gtr:id>2C432502-FE35-4436-9185-6852C7D3E6F9</gtr:id><gtr:impact>Proof of concept studies for new drugs entering clinic. Has led to clinical track nomination of 2 drug candidates with GSK</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>TJL mouse model of CNV</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52274E9F-190D-4A28-9197-A6797D3EF37B"><gtr:id>52274E9F-190D-4A28-9197-A6797D3EF37B</gtr:id><gtr:title>A2E induces IL-1&amp;szlig; production in retinal pigment epithelial cells via the NLRP3 inflammasome.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8c997e757c6319dd090a2cad27e2bbfe"><gtr:id>8c997e757c6319dd090a2cad27e2bbfe</gtr:id><gtr:otherNames>Anderson OA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/433EE24D-B3B8-4C09-B453-C5C4C2D8283D"><gtr:id>433EE24D-B3B8-4C09-B453-C5C4C2D8283D</gtr:id><gtr:title>VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7e52d4a3d73dc6c7fc5864785c141332"><gtr:id>7e52d4a3d73dc6c7fc5864785c141332</gtr:id><gtr:otherNames>Foxton RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0502B19A-4B09-437A-9EC4-B309F4BBD9C7"><gtr:id>0502B19A-4B09-437A-9EC4-B309F4BBD9C7</gtr:id><gtr:title>Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2985b154f88f72c9bbaa92d8ea6ae454"><gtr:id>2985b154f88f72c9bbaa92d8ea6ae454</gtr:id><gtr:otherNames>Nagai N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3F9BE0DF-C78A-4BA1-B266-454107729062"><gtr:id>3F9BE0DF-C78A-4BA1-B266-454107729062</gtr:id><gtr:title>Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2985b154f88f72c9bbaa92d8ea6ae454"><gtr:id>2985b154f88f72c9bbaa92d8ea6ae454</gtr:id><gtr:otherNames>Nagai N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E89F7437-8B55-4D42-9464-4BE41BA4F2D0"><gtr:id>E89F7437-8B55-4D42-9464-4BE41BA4F2D0</gtr:id><gtr:title>Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3c340fcc0e6654cf4ac06274da7dbab7"><gtr:id>3c340fcc0e6654cf4ac06274da7dbab7</gtr:id><gtr:otherNames>Robbie SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800946</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>